Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1491 Articles

Paul Ausick | May 5, 2014 at 8:00 AM EDT

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower…

Jon C. Ogg | May 4, 2014 at 10:32 AM EDT

The Top Eight Earnings for the Week Ahead

Jon OggEarnings season is far from over, but roughly three quarters of the stocks in the Standard & Poor’s 500 Index…

Paul Ausick | May 2, 2014 at 8:55 AM EDT

AstraZeneca Declares Pfizer Bid ‘Inadequate’

British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion…

Paul Ausick | Apr 28, 2014 at 4:01 PM EDT

The 4 Stocks That Led Markets Higher

thinkstockApril 28, 2014: Markets opened higher on Monday with little economic data to drive the market either up or down.…

cgblaine22 | Apr 26, 2014 at 8:30 AM EDT

Biotech: The Poster Child for Market Volatility in 2014

The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5.…

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Paul Ausick | Apr 21, 2014 at 4:40 PM EDT

The 4 Stocks That Boosted Markets

thinkstockApril 21 2014: Markets opened higher on Monday but there wasn’t a lot of action as the only data out…

Jon C. Ogg | Apr 21, 2014 at 1:25 PM EDT

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you…

Jon C. Ogg | Apr 16, 2014 at 10:40 AM EDT

Why Lpath Could Rise 300%

Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes…

Paul Ausick | Apr 7, 2014 at 4:27 PM EDT

The 4 Stocks That Slammed the Market

thinkstockApril 7, 2014: Markets opened lower on Monday and were on a downhill slide all day long. Momentum stocks again…

Jon C. Ogg | Apr 7, 2014 at 11:00 AM EDT

FDA Keeps Driving Up Future Cost of Inhalable Insulin

While the FDA has been far from a friend to MannKind over the past few years, the latest FDA panel…

Paul Ausick | Apr 1, 2014 at 7:50 AM EDT

U.S. Companies Park $947 Billion Offshore

ThinkstockWhen the S&P 500 index rises more than 25% in a year, you have to figure that some of the…

Paul Ausick | Mar 26, 2014 at 9:05 AM EDT

Telecoms Liven Up Short Interest in Big Dividend Stocks

ThinkstockThe short interest data for the first two weeks of March is out, and the results among the top high-yield…

Trey Thoelcke | Mar 26, 2014 at 8:45 AM EDT

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large…

Paul Ausick | Mar 24, 2014 at 4:01 PM EDT

The 4 Stocks That Pushed Stocks Lower on Monday

thinkstockMarch 24, 2014: Markets opened slightly higher on Monday but soon took a turn south and spent most of the…

1 … 66 67 68 69 70 … 100

Pfizer : PFE

All Pfizer Articles

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

The Top Eight Earnings for the Week Ahead

AstraZeneca Declares Pfizer Bid ‘Inadequate’

The 4 Stocks That Led Markets Higher

Biotech: The Poster Child for Market Volatility in 2014

UBS Top Stocks to Buy Working for Cancer Cures

The 4 Stocks That Boosted Markets

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Why Lpath Could Rise 300%

The 4 Stocks That Slammed the Market

FDA Keeps Driving Up Future Cost of Inhalable Insulin

U.S. Companies Park $947 Billion Offshore

Telecoms Liven Up Short Interest in Big Dividend Stocks

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

The 4 Stocks That Pushed Stocks Lower on Monday

Procter & Gamble vs. Colgate-Palmolive: One Dividend Giant Stands Above the Rest

Jim Cramer: CoreWeave’s Backlog ‘May Be Much Greater’ Than Wall Street Thinks

Google, SpaceX, Microsoft, and Amazon Are About to Spend ‘Twice the Entire U.S. Defense Budget’ on AI

SECURE 2.0 Changes Force High Earners to Rethink 401(k) Strategy. Here's the Math.

The RFK Jr. Medicare AI Program Already Denying Seniors Care in 6 States

Procter & Gamble vs. Colgate-Palmolive: One Dividend Giant Stands Above the Rest

Jim Cramer: CoreWeave’s Backlog ‘May Be Much Greater’ Than Wall Street Thinks

Pfizer : PFE

All Pfizer Articles

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

The Top Eight Earnings for the Week Ahead

AstraZeneca Declares Pfizer Bid ‘Inadequate’

The 4 Stocks That Led Markets Higher

Biotech: The Poster Child for Market Volatility in 2014

UBS Top Stocks to Buy Working for Cancer Cures

The 4 Stocks That Boosted Markets

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Why Lpath Could Rise 300%

The 4 Stocks That Slammed the Market

FDA Keeps Driving Up Future Cost of Inhalable Insulin

U.S. Companies Park $947 Billion Offshore

Telecoms Liven Up Short Interest in Big Dividend Stocks

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

The 4 Stocks That Pushed Stocks Lower on Monday

Procter & Gamble vs. Colgate-Palmolive: One Dividend Giant Stands Above the Rest

Jim Cramer: CoreWeave’s Backlog ‘May Be Much Greater’ Than Wall Street Thinks

Google, SpaceX, Microsoft, and Amazon Are About to Spend ‘Twice the Entire U.S. Defense Budget’ on AI

Featured Reads

SECURE 2.0 Changes Force High Earners to Rethink 401(k) Strategy. Here's the Math.

The RFK Jr. Medicare AI Program Already Denying Seniors Care in 6 States